Compare Eli Lilly And Co (LLY) vs Raytheon Technologies Corp (RTX) Price & Performance

Eli Lilly (LLY) trades at $1,223.97, down 0.62% on the day, maintaining strong bullish momentum with consecutive earnings beats and robust revenue growth. The stock shows technical strength above key support levels at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 102.44% ROE. Recent quarterly results exceeded expectations, with Q2 2026 revenue surging 48% to $23 billion driven by Mounjaro and Zepbound demand.

Outlook remains positive with analyst consensus targeting $1,380 and 73% buy ratings, though elevated valuations (P/E 40.8) and regulatory risks around weight-loss drug competition present headwinds. The company's pipeline advancement with retatrutide filing expected in 2027 provides medium-term growth catalysts, but investors should monitor execution risks in the competitive obesity drug market.

RTX trades at $223.86, down 0.12% on the day, with a bullish technical signal and strong analyst consensus. Recent earnings beats, including Q2 2026 EPS of $1.89 versus $1.66 expected, and a $515 million Navy contract for SPY-6 radars (PRNewsWire, June 3, 2026) highlight operational strength. The stock shows robust cash flow growth, with 2025 operating cash flow at $10.57 billion, and a net income margin of 8.28%.

Outlook is positive with a consensus price target of $233.14 (Barron's, June 2026), supported by defense sector tailwinds and innovation in munitions manufacturing. Risks include high debt levels and geopolitical uncertainties. The valuation at a P/E of 39.41 suggests premium pricing, requiring sustained earnings growth for further upside.